Review ofHelicobacter pyloriEradication Regimens

Abstract

A sensitivity test comparing the effect of different study designs on eradication rates showed that study quality has no conclusive impact on success rates. The two dual therapies, together with the H2-receptor antagonist triple therapies, are less effective than triple therapies with omeprazole. Bismuth-based triple therapies have a mean overall eradication rate of 79%, but are limited by frequent and significant side-effects causing poor drug compliance. Data on lansoprazole triple therapies are almost non-existent, while data on omeprazole triple therapies are extensive and consistently show eradication rates of close to or above 90%.